Description
Gina Columbus reports on a breakthrough therapy designation in cutaneous squamous cell carcinoma, a biologics license application for a biosimilar, clinical holds placed on trials in multiple myeloma and other hematologic malignancies, and highlights from the 2017 ESMO Congress.
Tags
cancer oncology